Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 9:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Celecoxib 200 mg BID Clear all
Completed Phase 3 Interventional Results available

Study of Indomethacin Capsules to Treat Pain Following Bunionectomy

NCT01543685
View directory record Official record
Conditions
Other Acute Postoperative Pain
Interventions
Indomethacin, Celecoxib, Placebo
Drug
Lead sponsor
Iroko Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
4
States / cities
Phoenix, Arizona • Pasadena, Maryland • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Sep 23, 2026, 9:27 PM EDT
Completed Phase 1Phase 2 Interventional Results available

αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies

NCT02151448
View directory record Official record
Conditions
Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface, Malignant Peritoneal Mesothelioma, Peritoneal Carcinomatosis
Interventions
DC vaccine, Celecoxib, Interferon Alfa-2b, rintatolimod
Biological · Drug
Lead sponsor
David Bartlett
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 19, 2020 · Synced Sep 23, 2026, 9:27 PM EDT
Completed Phase 3 Interventional Results available

A Six Week Study Of The Pain Relieving Effects Of Celecoxib 200 Mg Twice Daily Compared To Tramadol 50 Mg Four Times Daily In Patients With Chronic Low Back Pain

NCT00662558
View directory record Official record
Conditions
Low Back Pain
Interventions
celecoxib, tramadol HCL
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
60
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 23, 2026, 9:27 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Variability in Response to Non-steroidal Anti-inflammatory Drugs

NCT02502006
View directory record Official record
Conditions
Healthy
Interventions
Celecoxib, Naproxen, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Sep 23, 2026, 9:27 PM EDT
Completed Phase 2 Interventional Results available

Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery

NCT00466505
View directory record Official record
Conditions
Colorectal Cancer
Interventions
cetuximab, celecoxib, proteomic profiling, immunohistochemistry staining method, laboratory biomarker analysis, mass spectrometry
Biological · Drug · Genetic + 1 more
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 18, 2012 · Synced Sep 23, 2026, 9:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Comparison of Small Bowel Lesions Associated With Celecoxib Versus Ibuprofen Plus Omeprazole

NCT00640809
View directory record Official record
Conditions
Bowel Diseases, Inflammatory
Interventions
Celecoxib, Placebo, Ibuprofen plus Omeprazole
Drug · Other
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
408 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
12
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Sep 23, 2026, 9:27 PM EDT
Completed Phase 3 Interventional

Study Evaluating the Efficacy and Safety of Topical Diclofenac Spray in Osteoarthritis of the Knee: Trial II

NCT00546832
View directory record Official record
Conditions
Osteoarthritis
Interventions
TDS-943 (topical diclofenac sodium 4% spray), celecoxib, placebo
Drug · Other
Lead sponsor
Mika Pharma GmbH
Industry
Eligibility
40 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
49
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2010 · Synced Sep 23, 2026, 9:27 PM EDT
Completed Phase 3 Interventional

Study Evaluating the Efficacy and Safety of Topical Diclofenac Spray in Osteoarthritis of the Knee: Trial I

NCT00546507
View directory record Official record
Conditions
Osteoarthritis
Interventions
TDS-943 (topical diclofenac sodium 4% spray), celecoxib, placebo
Drug · Other
Lead sponsor
Mika Pharma GmbH
Industry
Eligibility
40 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
43
States / cities
Huntsville, Alabama • Mobile, Alabama • Mesa, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2010 · Synced Sep 23, 2026, 9:27 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Zileuton With or Without Celecoxib As Chemopreventive Agents in Smokers

NCT01021215
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Zileuton, Celecoxib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Sep 23, 2026, 9:27 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis

NCT00664560
View directory record Official record
Conditions
Osteoarthritis
Interventions
PN 400 (VIMOVO), celebrex, Placebo, Rescue Antacid
Drug
Lead sponsor
POZEN
Industry
Eligibility
50 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 26, 2012 · Synced Sep 23, 2026, 9:27 PM EDT
Terminated Phase 2 Interventional Results available

Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients

NCT05077969
View directory record Official record
Conditions
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection, COVID-19, COVID-19 Pandemic, COVID-19 Virus Disease, COVID-19 Virus Infection, Covid19, Coronavirus Disease 2019, SARS-CoV2 Infection, SARS-CoV-2 Acute Respiratory Disease
Interventions
Famotidine, Celecoxib, Placebo
Drug
Lead sponsor
Leidos Life Sciences
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Newport Beach, California • Miami, Florida • Atlanta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2024 · Synced Sep 23, 2026, 9:27 PM EDT
Completed Phase 2 Interventional Results available

Open-Label CA-008 (Vocacapsaicin) in Bunionectomy

NCT03885596
View directory record Official record
Conditions
Pain
Interventions
CA-008, Ketorolac, Acetaminophen IV, Fentanyl, Bupivacaine Hydrochloride, Lidocaine HCl, Celecoxib, Acetaminophen Oral, Lidocaine Hydrochloride, Exparel
Drug
Lead sponsor
Concentric Analgesics
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Sep 23, 2026, 9:27 PM EDT
Terminated Phase 1 Interventional

The Seven Trial: Exploiting the Unfolded Protein Response

NCT06076837
View directory record Official record
Conditions
Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic
Interventions
Botensilimab, Balstilimab, Chloroquine Phosphate, Celecoxib, Nab paclitaxel, Gemcitabine, Cisplatin
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 23, 2026, 9:27 PM EDT
Completed Phase 4 Interventional Results available

Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen

NCT00346216
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
celecoxib, Ibuprofen, Naproxen
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
24,081 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
871
States / cities
Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 515 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Sep 23, 2026, 9:27 PM EDT
Completed Phase 2 Interventional

LEAP-CT for Treatment of COVID-19 Patients (Master Protocol)

NCT05077332
View directory record Official record
Conditions
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection, COVID-19 Pandemic, COVID-19 Virus Disease, COVID-19 Virus Infection, Covid19, Coronavirus Disease 2019, SARS-CoV-2 Infection, SARS-CoV-2 Acute Respiratory Disease, COVID-19
Interventions
Famotidine, Celecoxib, Placebo
Drug · Other
Lead sponsor
Leidos Life Sciences
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 23, 2026, 9:27 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Celecoxib as a Chemopreventive Agent in Current and Former Smokers

NCT00981201
View directory record Official record
Conditions
Smoking, Prevention
Interventions
Celecoxib, Placebo
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 74 Years
Enrollment
219 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Sep 23, 2026, 9:27 PM EDT
Terminated Phase 2 Interventional Results available

Individualizing Anti-Inflammatory Medications for Adults With Axial Spondyloarthritis: A Series of N-of 1 Trials

NCT04115098
View directory record Official record
Conditions
Axial Spondyloarthritis
Interventions
Celecoxib, Naproxen, Meloxicam
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Sep 23, 2026, 9:27 PM EDT
Not yet recruiting Phase 4 Interventional

Examining Analgesic Synergy and Efficacy in Trauma Care

NCT07435077
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine, Oxycodone
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 23, 2026, 9:27 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Celecoxib Inhibition of Aromatase Expression and Inflammation in Adipose Tissue of Obese Postmenopausal Women

NCT01901679
View directory record Official record
Conditions
Obesity
Interventions
Celebrex
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
40 Years to 70 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2021 · Synced Sep 23, 2026, 9:27 PM EDT
Terminated Phase 2 Interventional Results available

Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Rectal Cancer

NCT00250835
View directory record Official record
Conditions
Rectal Cancer
Interventions
Chemotherapy, Celecoxib, and Radiation
Other
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
3
States / cities
Albuquerque, New Mexico • Santa Fe, New Mexico
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced Sep 23, 2026, 9:27 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Celecoxib and Radiation Therapy in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer

NCT00046839
View directory record Official record
Conditions
Lung Cancer
Interventions
celecoxib, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
44
States / cities
Colorado Springs, Colorado • Gainesville, Florida • Jacksonville, Florida + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Sep 23, 2026, 9:27 PM EDT
Completed Phase 4 Interventional

Safety and Efficacy of Celecoxib Versus Naproxen in the 6-month Treatment of Knee Osteoarthritis

NCT00643799
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Celecoxib, Naproxen, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
40 Years and older
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
51
States / cities
Montgomery, Alabama • Phoenix, Arizona • Tempe, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Sep 23, 2026, 9:27 PM EDT
Completed Phase 2 Interventional Results available

Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer

NCT00201773
View directory record Official record
Conditions
Breast Cancer
Interventions
Exemestane, Celecoxib, Correlative studies
Drug · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Sep 23, 2026, 9:27 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis

NCT00665431
View directory record Official record
Conditions
Osteoarthritis
Interventions
PN 400 (VIMOVO), celebrex, Placebo, Rescue Antacid
Drug · Other
Lead sponsor
POZEN
Industry
Eligibility
50 Years and older
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 5, 2011 · Synced Sep 23, 2026, 9:27 PM EDT